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Objective: The aim of the study was to identify genetic variants predisposing to primary hip and knee
osteoarthritis (OA) in a sample of Finnish families.
Methods: Genome wide analysis was performed using 15 independent families (279 individuals) origi-
nating from Central Finland identiﬁed as having multiple individuals with primary hip and/or knee OA.
Targeted re-sequencing was performed for three samples from one 33-member, four-generation family
contributing most signiﬁcantly to the LOD score. In addition, exome sequencing was performed in three
family members from the same family.
Results: Genome wide linkage analysis identiﬁed a susceptibility locus on chromosome 2q21 with a
multipoint LOD score of 3.91. Targeted re-sequencing and subsequent linkage analysis revealed a sus-
ceptibility insertion variant rs11446594. It locates in a predicted strong enhancer element region with
maximum LOD score 3.42 under dominant model of inheritance. Insertion creates a recognition
sequence for ELF3 and HMGA1 transcription factors. Their DNA-binding afﬁnity is highly increased in the
presence of A-allele compared to wild type null allele.
Conclusion: A potentially novel functional OA susceptibility variant was identiﬁed by targeted re-
sequencing. This variant locates in a predicted regulatory site and creates a recognition sequence for
ELF3 and HMGA1 transcription factors that are predicted to play a signiﬁcant role in articular cartilage
homeostasis.
© 2015 The Authors. Published by Elsevier Ltd and Osteoarthritis Research Society International. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Epidemiological studies of family history and family clustering,
twin studies, and exploration of rare genetic disorders related to
osteoarthritis (OA) have shown that hereditary factors have aM. M€annikk€o, Center for Life
y of Medicine, University of
Tel: 358-(0) 294-485751.
nikk€o).
r Ltd and Osteoarthritis Research Ssigniﬁcant role in the development of this condition1. Estimated
prevalence of hip and knee OA varies widely in epidemiological
studies2,3, but taken together, these conditions afﬂict several
percent of working age and elderly men and women, causing also a
substantial ﬁnancial burden among all western populations.
Several genomewide linkage studies with families affected with
hand and hip OA have been performed in order to ﬁnd new sus-
ceptibility genes for OA. These scans have indicated suggestive
linkage to most chromosomes, strengthening the hypothesis that
the genetic etiology of this disease may be more complex thanociety International. This is an open access article under the CC BY-NC-ND license
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families have revealed linkage to multiple chromosomal areas
including 2q, 4q, 6p (women), 11q, 16p and 16q (women) (reviewed
in4). In addition to numerous OA associating loci reported in larger
population based studies, there are also previous reports of rare
familial forms of OA where disease seems to be transmitted in
families in a dominant manner5,6.
Only large effect size alleles or variants can be detected by
linkage analysis, while genome-wide association studies (GWAS)
identify common small effect alleles. For different OA phenotypes
several GWAS have been conducted7e9. It has become apparent that
most of the OA associated alleles, such as the ones in GDF5 and
DIO2, contribute by modifying gene expression at transcriptional
level10,11. However, only few genome-wide signiﬁcant associations
have been identiﬁed and they explain only a small proportion of the
heritability. Recently, the focus in identifying disease causing
sequence variants has been in the next-generation sequencing
(NGS) technology, which allows identifying rare causal variants
with a large effect size. NGS has successfully been used to identify
causative variants in other diseases such as in prostate cancer12 and
schizophrenia13.
Discovering new risk genes for genetically complex disease such
as OA is challenging. This is partly due to the multiform etiology of
the disease. No major disease causing variants have been identiﬁed
so far, even though many variants in several genes have been
implicated through previous linkage scans and following associa-
tion analyses. Here we have conducted a family-based linkage
analysis with subsequent targeted re-sequencing of the linkage
region. To restrict the heterogeneity we have focused on 15 Finnish
families with early-onset primary OA.
Patients and methods
Families
Initially ten independent families with early-onset OA were
recruited for the genome wide linkage analysis. Additional ﬁve
families were collected for the ﬁne mapping, making the total
number of studied families ﬁfteen. Probands of each family were
identiﬁed through the patient registers of Jyv€askyl€a and Kuopio
central hospitals, both located in Central Finland. All living family
members of each proband were contacted and interviewed for the
study. Ten families that were used for the whole genome scan
included a total of 225 individuals, with the pedigree size ranging
from 11 to 37 individuals. The inclusion criterion for the genome
wide analysis was the presence of at least two affected individuals
in each family who had hip and/or knee OA. The additional ﬁve
families included a total of 54 individuals, with the pedigree size
ranging from 8 to 14. At least three family members in each family
were required to have hip and/or knee OA diagnosis while at least
two of the affected individuals had to be ﬁrst degree relatives.
Taken together, 279 individuals in 15 families were analyzed,
including 58 individuals with OA diagnoses of the hip and/or knee
and 34 subjects that were considered healthy. OA status of 185
subjects was considered unknown, as described in detail later. The
study was approved by local ethical committees and all subjects
signed an informed written consent.
Clinical and radiological assessment
Probands in each family had gone through or were currently
waiting for endoprosthetic hip and/or knee replacement due to OA.
Their living adult relatives were ﬁrst interviewed personally fol-
lowed by a questionnaire in order to obtain adequate information
about individual medical histories, possible OA diagnosis andformer as well as current joint symptoms. Subjects with a history of
a signiﬁcant hip or knee joint trauma or obesity were excluded from
the analyses or their OA status were deﬁned as unknown to in-
crease the power to detect actual genetic risk factors. Similarly
families and individuals with a history, clinical ﬁndings or symp-
toms of any inﬂammatory joint disease, such as rheumatoid
arthritis (RA) or any other local or systemic rheumatic disease/
condition were excluded. All family members reporting joint
symptoms in hip and/or knee joints were clinically evaluated for
the presence of OA. Nearly all of the OA affected subjects had gone
through or were currently waiting for hip and/or knee joint
replacement. Standard radiological examination of symptomatic
hip or knee joint(s) was performed and diagnosis of OA in this study
was based on two main criteria: presence of common OA symp-
toms and typical radiological ﬁndings associated with OA observed
in the standard joint X-ray projections. Common symptoms
included signiﬁcant joint pain (in movement and/or at rest), stiff-
ness and possibly a decreased ability to move and use the affected
joint. Diagnosis was conﬁrmed if radiological evaluation of symp-
tomatic joints showed at least moderately severe narrowing of joint
space and one or more of the other OA speciﬁc changes: sub-
chondral bone sclerosis, osteophytes or joint deformity. Even
though standard clinical evaluation was performed, no systematic
grading of the level of radiologically diagnosed OA with Kell-
greneLawrence or other scales was made. Studied subjects were
considered healthy if they had never suffered from any prolonged
joint symptoms concerning hip or knee joints; and in these cases,
no radiological imaging of the hip or knee joints was systematically
made. Pure radiological OA (rOA) without any symptoms was thus
not considered a relevant variable in this study. Borderline cases
with atypical symptoms or inadequate radiological ﬁndings were
not included in either group in the analysis. A detailed overview of
the characteristics of this study sample is presented in Table I.
Genotyping for linkage analysis
Genomic DNA was extracted from the white blood cells of the
subjects using standard protocols. Genotyping for genome wide
linkage scan was performed at the Finnish Genome Center (Hel-
sinki, Finland) using the Applied Biosystems Linkage Mapping Set
(MD 10) and an automated instrument (Megabase 1000; Molecular
Dynamics).
In the ﬁrst ﬁne mapping additional markers (http://www.ncbi.
nlm.nih.gov) spaced 2e5 cM apart were selected for the regions
of interest on chromosomes 2 and 11 (10 and 7 markers, respec-
tively). The genotyping was performed using standard
ﬂuorescence-based genotyping methodologies (ABI PRISM 3100
Genetic Analyzer, Applied Biosystems). After denaturation with
formamide at 90C for 2 min, products were separated by size and
were detected using ABI PRISM 3100 genetic analyzer (Applied
Biosystems). In the second ﬁne mapping, 15 additional markers
from chromosome 2 and 10 markers from chromosome 11 were
genotyped to gain average ~1 cM spacing between markers. Gen-
otyping was performed using GeneMapper Software version 4.0
(Applied Biosystems).
Statistics in linkage analysis
All genotypes were checked for Mendelian incompatibilities
using PedCheck 1.114. Allele frequencies were estimated at each
locus from the data using observed and reconstructed genotypes of
founders within the pedigrees. Age dependent penetrance models
were used in linkage analysis (available on request). Both para-
metric and non-parametric multipoint LOD scores were calculated
with Simwalk2 version 2.9115. Two-point LOD scores were
Table I
Characteristics of the studied families with the deﬁnitions of the OA outcomes
Family n Male Female Hip OA Knee OA Knee & Hip OA Healthy Unknown
1* 22 11 11 0 1 0 4 17
2 11 4 7 0 3 0 2 6
3 20 10 10 0 3 1 5 11
4 29 14 15 2 0 1 3 23
5 14 8 6 1 1 2 2 8
6 31 13 18 1 2 2 2 24
7 14 6 8 0 3 0 1 10
8 14 8 6 3 0 1 1 9
9 37 16 21 0 2 2 3 30
10 33 17 16 5 1 4 6 17
11 14 8 6 3 2 0 1 8
12 13 9 4 5 0 0 1 7
13 10 6 4 2 0 1 0 7
14 8 4 4 2 0 1 2 3
15 9 3 6 1 2 0 1 5
All 279 137 142 25 20 15 34 185
* Three affected individuals were identiﬁed in family 1, but DNA was available only from one.
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version 5.216. The disease-allele frequency was set at 0.001. Genetic
distances (cM) and microsatellite marker locations were speciﬁed
according to database of the National Center for Biotechnology
Information (http://www.ncbi.nlm.nih.gov/).
Targeted re-sequencing and variant detection
One healthy (II-6) and two affected family members (II-9, III-26)
of the same family [Fig. 1] were chosen for targeted re-sequencing.
The entire 15.5 Mb segment of chromosome 2 containing the
linkage peak and neighboring regions (126216105e141687523
GrCh37) was targeted by NimbleGen Sequence Capture 2.1M array
(Roche) and the sequencing was performed by The Genome
Analyzer IIx (Illumina). Alignment of sequence reads to reference
and visualization, and variant detection, were done by a bioinfor-
matics pipeline at the Institute of Molecular Medicine Finland
(FIMM)17.
Variant annotation and ﬁltering
ANNOVAR software18 and SNPnexus program (http://snp-nexus.
org/)19 was used for variant annotation and ﬁltering. A custom
pipeline with following criteria was used: (1) in silico pathogenicity
using UCSC RefGene database to annotate variants as nonsense,
splice, missense, synonymous, UTR, or noncoding was estimated;
(2) variants with minor allele frequency (MAF) > 5% in the 1000
Genomes Project April 2012 release were removed; (3) the dbSNP
version 137 was used in search of known SNPs, however, it was notFig. 1. Pedigree structure of family 10. A black dot beneath an individual indicates that D
unknown clinical status. Asterisk denotes individuals that were exome sequenced and opeused for ﬁltering, since the database may include disease causing
variants; (4) functional effects with whole-exome SIFT scores
(version 2), whole-exome PolyPhen scores, whole-exome PolyPhen
2 scores built on HumanDiv database (for complex phenotypes),
whole-exomeMutationTaster scores (version 2) were predicted; (5)
conserved regions and transcription factor binding sites using
whole-exome GERPþþ scores and phastCons 46-way alignments
were screened, respectively; (6) non-coding variants that disrupt
enhancers, repressor or promoter regions were identiﬁed using
HMM (Hidden Markov models) predictions for skeletal muscle
myoblasts (HSMM) and B-lymphocyte (GM12878) cell lines20; (7)
DNase I hypersensitivity regions and segmental duplications were
estimated.Exome sequencing and variant detection
In addition to the targeted re-sequencing three affected in-
dividuals from family 10 were selected for exome sequencing in
Beijing Genome Institute, Hong Kong. For exome capture and target
sequencing SureSelect 51M Capture Kit (Agilent Technologies) and
IlluminaHiSeq2000 100PE Platform were used, respectively. The
paired-end sequence reads were aligned with Burrows-Wheeler
Alignment tool21. Initial variant calling was performed using
Genome Analysis ToolKit (GATK)22. Computational analysis of the
whole exome data was done using the 64-bit Red Hat Enterprise
Linux Server release 6/Hippu, IT Center for Science Ltd (CSC). Var-
iants were ﬁltered by GATK and single nucleotide variants (SNVs)
with mapping quality (MQ) < 40, Haplotype score > 13 and geno-
type quality (GQ) < 20 were excluded. Small insertions or deletionsNA was available for genetic analysis. Individuals marked with question marks have
n circles targeted re-sequenced individuals.
Fig. 2. Multipoint and two-point LOD scores from the second ﬁne mapping on
chromosome 2 under a recessive mode of inheritance.
M. Taipale et al. / Osteoarthritis and Cartilage 24 (2016) 655e663658(indels) with quality by depth (QD) < 2.0, ﬁsher strand >200.0 and
Read Position Rank Sum Test < 20.0 were excluded. Comparison
of the exome data between individuals was done using BEDTools23.
Annotation of variants with ANNOVAR software was performed as
described previously.
Variant validation for Pseudomarker analysis
Altogether 32 variants that located within regulatory regions
(n ¼ 20, targeted re-sequencing) or gained harmful prediction
(n ¼ 12, exome sequencing) were genotyped in family 10
(Suppl. Table I). Genotyping was performed by Sanger sequencing
using ABI PRISM 3500xl Genetic Analyzer (Applied Biosystems) and
Variant Reporter Software 2 (Applied Biosystems). Primer se-
quences are available on request. Pseudomarker version 2.0 was
used to evaluate the evidence for linkage and association in the
candidate region pointed out by the whole genome linkage anal-
ysis. Pseudomarker is able to analyze linkage and association both
separately and jointly and analyze different pedigree structures,
trios, cases and controls24,25. Recessive, dominant and model based
models of Pseudomarker were used in analysis. Two variants,
rs200661871 and rs11446594, with highest LOD scores, were gen-
otyped among all 15 families.
Bioinformatic analyses with Enhancer Element Locator
Enhancer Element Locator (EEL)26 software was used to predict
weather rs200661871 and rs11446594 directly affect DNA-binding
motifs for certain transcription factors. Surrounding sequences of
rs200661871 and rs11446594 were analyzed with DNA-binding
speciﬁcity data set for human transcription factors27.
Results
Clinical and radiological ﬁndings
In ﬁfteen families, 25 hip OA, 20 knee OA and 15 subjects with
OA in both joints were identiﬁed from a total of 279 studied sub-
jects. The average age at the disease onset in this study was 50
years. Thirty-four subjects were classiﬁed as healthy and 185 in-
dividuals as unknown in the analyses. The pedigree of the largest
family (family 10) is presented in Fig. 1.
Genome-wide linkage analysis
In the whole genome scan, a total of ten hip and knee OA fam-
ilies were analyzed. Two-point linkage analysis identiﬁed four
interesting loci on chromosomes 2, 11, 13 and 20 with logarithm of
odds (LOD) scores above 1.5. In multipoint analysis a maximum
overall LOD score of 2.14 occurred on chromosome 2 between
markers D2S112 and D2S142 indicating the same region as in the
two point analysis. The second highest peak was detected on
chromosome 11 with a maximum multipoint LOD score of 1.82.
There were no peaks exceeding the threshold of 1.5 for the multi-
point analysis in other chromosomes (data not shown).
The two most interesting loci on chromosomes 2 and 11 with
LOD scores over 1.5 in both two-point and multipoint analyses,
were further analyzed by ﬁne mapping, including ﬁve additional
families. After the second ﬁne mapping only one family (Family 10,
Fig. 1) contributed signiﬁcantly to the LOD score, whereas other
families contributed only slightly. The ﬁne mapping conﬁrmed the
susceptibility locus on chromosome 2 with a multipoint LOD score
of 3.91 under a recessivemodel of inheritance. The same regionwas
indicated in two-point linkage analysis resulting in a maximum
two-point LOD score of 3.63 at a recombination fraction of 0.00 forlocus D2S1260 [Fig. 2]. The linkage signal for chromosome 11 dis-
appeared after ﬁne mapping. No statistically signiﬁcant results
were obtained using dominant model of inheritance in either
chromosomal locus.Targeted re-sequencing and prioritized candidate variants
The 15.5 Mb region identiﬁed in linkage analysis on chromo-
some 2 was re-sequenced using NGS technology. The average 20-
fold coverage for target region was >89%. Sequencing resulted in
26,078 high quality variant calls (reference sequence GRCh37). Two
affected family members shared 4006 variant calls. Out of these
4006 variant calls 475 had MAF 0.05 or the frequency was un-
known according to 1000 Genomes Project 2012 April release on
European subjects, and 63 (1.6%) were not previously annotated in
dbSNP (http://www.ncbi.nlm.nih.gov/snp). Only 16 were exonic
but they all were synonymous or benign according to computa-
tional pathogenicity estimates as described above. Seventeen var-
iants were identiﬁed to target enhancers, repressor or promoter
regions according to HMM predictions for HSMM or GM12878 cell
lines. In addition, targeted sequencing identiﬁed 659 indels, which
were shared by the two affected family members and were not
found in the healthy relative. All the indels were intronic or inter-
genic and three of them with MAF 0.05 or unknown frequency
located in predicted regulatory regions according to HMM pre-
dictions for HSMM or GM12878 cell lines. General statistics of the
targeted re-sequencing and variant prioritization are shown in
Table II.Exome sequencing and prioritized candidate variants
Variant calling resulted to an average of 77,755 SNVs and 8852
indels. Average sequencing depth in target area was 67X and the
average coverage of target region was 92%. Filtering by quality
resulted in average of 70,333 SNVs and 8776 indels. Comparison by
BEDTools showed that the three affected family members shared
39,039 SNVs and 4797 indels. Functional annotation by ANNOVAR
revealed ﬁve SNVs and one indel with MAF 0.01 or private exonic
variants with pathogenic annotations. In addition six rare or private
SNVs were found on active promoter sites or strong enhancer areas.
Table II
General statistics of the sequencing run and variant annotation of the targeted
re-sequencing and exome sequencing
Coverage statistics Variant statistics
Targeted re-sequencing
Total number of
mapped bases
11,267 512 Variants detected 26,078
Target 20-fod coverage SNVs shared
by the affected
4006
III-26 88.26% MAF< 0.05 475
II-9 91.12% Novel variants 63
II-6 88.26% Regulatory region 17
Indels shared
by affected
659
Regulatory region 3
Exome sequencing
The average coverage of target region SNVs shared
by the affected
39,039
III-26 91,84% MAF< 0.01 94
IV-33 92,12% Novel variants 212
II-13 92,42% Harmful 11
Indels shared
by the affected
4797
MAF< 0.01 19
Novel variants 326
Harmful 1
Numbering of the individuals is according to Figure 1.
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tion are shown in Table II.
Pseudomarker and EEL analysis
None of the selected 12 variants with harmful prediction from
exome sequencing were found in all affected family members of
family 10, and thus were not analyzed further (data not shown).
Predicted regulatory region variants from targeted re-sequencing
were analyzed using Pseudomarker analysis software. The results
are shown in Table III. Moderate evidence for linkage was found forTable III
Results of the Pseudomarker single-point linkage analysis
Position (hg19) snp137 MAF Gene Location
127166786 rs191705727 0.004 CNTNAP5, GYPC Intergenic, GERP sco
127414803 rs115260878 0.03 GYPC Intronic, strong enha
127415578 rs112991427 0.03 GYPC Intronic, active prom
127417098 rs116012614 0.03 GYPC Intronic, strong enha
127420383 rs112745348 0.04 GYPC Intronic, strong enha
127832275 rs138530867 NAx BIN1 Intronic, strong enha
127832682 rs141817721 0.003 BIN1 Intronic, strong enha
128146026 rs192154491 0.01 MAP3K2, PROC Intergenic, active pr
129864234 rs141185315 0.05 HS6ST1, LOC389033 Intergenic, weak enh
130691676 NA NA LOC389033 Intronic, active prom
130939163 rs146359515 0.01 SMPD4 Exonic, active promo
132127004 rs200661871 NA WTH3DI, LINC01120 Intergenic, tfbs score
134570742 rs11446594 0.38* NCKAP5, MIR3679 Intergenic, strong en
134575035 rs116663953 0.02 NCKAP5, MIR3679 Intergenic, weak enh
137134616 rs148906434 0.01 CXCR4, THSD7B Intergenic, weak enh
137986076 rs115528720 0.03 THSD7B Intronic, weak enha
138709574 rs186666211 0.004 THSD7B, HNMT Intergenic, weak enh
138714163 NA NA THSD7B, HNMT Intergenic, strong en
138723086 rs145115612 0.0040 HNMT Intronic, weak prom
141311237 rs143690440 0.01 LRP1B Intronic, tfbs score 8
*1000 Genomes Project October 2014 release on European subjects. At the time of Annov
2012 release on European subjects.
* Model based analyses include liability classes.
y GERP ¼ the genomic evolutionary rate proﬁling.
z tfbs ¼ transcription factor binding site.
x NA ¼ not available.two heterozygous indels rs200661871 and rs11446594 located at
132127004 and 134570742 (hg19), respectively, with maximum
LOD score 2.34 under a dominant model of inheritance. According
to phastCons 46-way alignments and chromHMM predictions of
ANNOVAR program rs200661871 locates on a transcription factor
binding site and rs11446594 interrupts a strong enhancer element.
Furthermore, we conducted bioinformatics analysis using EEL al-
gorithm26, and found that rs11446594 is a motif-disruptor for the
transcription factors ELF3 and HMGA1. EEL prediction also showed
that ELF3 and HMGA1 indicate highly increased DNA-binding af-
ﬁnity to the rs11446594 A allele than null allele, suggesting that the
variant A at rs11446594 may create a recognition DNA sequence for
these transcription factors. These two variants were genotyped in
all 15 families (Table IV). In the following Pseudomarker analysis
insertion rs11446594 showed strong linkage (LOD score 3.42) un-
der a dominant model of inheritance, but only nominal evidence of
association (P ¼ 0.02) to OA. Insertion rs200661871 indicated some
evidence of linkage (LOD score 1.62), but did not show signiﬁcant
association (P ¼ 0.92) when studied in all families.Discussion
In the present study linkage analysis and targeted re-sequencing
identiﬁed a novel susceptibility locus for OA on chromosome 2q21
with two candidate variants, insertions rs11446594 and
rs200661871. Chromosome 2 has been among the most studied
chromosomes that are likely to harbor OA susceptibility genes.
Several different studies have indicated linkage to chromosome 2
(reviewed in4,28). However, the OA susceptibility locus identiﬁed in
this study does not overlap with these earlier ﬁndings. The highest
LOD score 3.91 in genome wide linkage analysis indicating strong
linkage to OA was achieved using a recessive model of inheritance.
However, the highest LOD score 3.42 in targeted linkage analysis
using Pseudomarker software was achieved using a dominant
model of inheritance, and all the affected family members in four-
generation family 10 were heterozygous for rs11446594 andRecessive LOD score Dominant LOD score
Model-free Model based* Model-free Model based
rey 3.54 0.558 0.551 0.067 0.064
ncer, active promoter 0.558 0.551 0.067 0.064
oter 0.557 0.551 0.065 0.062
ncer 0.558 0.551 0.067 0.064
ncer 0.558 0.551 0.067 0.064
ncer 0.023 0.026 0.000 0.000
ncer 0.558 0.551 0.067 0.064
omoter 0.558 0.551 0.067 0.064
ancer 0.750 0.751 0.312 0.367
oter 0.558 0.551 0.067 0.064
ter, tfbs scorez 885 0.558 0.551 0.067 0.064
793 1.806 1.707 2.346 1.868
hancer 1.806 1.707 2.341 1.907
ancer 1.806 1.705 0.342 0.269
ancer 1.806 1.705 0.342 0.269
ncer 1.806 1.705 0.343 0.368
ancer 1.806 1.705 0.343 0.368
hancer 1.806 1.705 0.343 0.368
oter 1.806 1.705 0.335 0.472
04 1.806 1.705 0.988 1.049
ar analysis, MAF of variant was unknown according to 1000 Genomes Project April
Table IV
Results of the Pseudomarker association analysis
Position (hg19) snp137 MAF Gene Location LOD score P value*
132127004 rs200661871 NA WTH3DI. LINC01120 Intergenic 1.62 0.92
134570742 rs11446594 NA NCKAP5. MIR3679 Intergenic 3.42 0.02
*non-corrected.
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rather than false-positive29. These results demonstrate the complex
inheritance pattern of OA with multiple risk loci and some of them
acting in a dominant-like fashion and others being more recessive-
like. A non-Mendelian inheritance pattern has been conﬁrmed in
several studies (reviewed in Peach et al. 2005)1.
Variant rs11446594 resides between the genes coding NCK-
associated protein 5 (NCKAP5) and microRNA 3679 (MIR3679),
and based on UCSC genome browser is located within a histone
H3K27ac and DNase I hypersensitivity site (ENCODE) [Fig. 3].
H3K27ac separates active enhancers from poised/inactive enhance
elements30 while DNase I hypersensitivity sites are chromosomal
areas that associatewith active gene loci and regulatory elements31.
Enhancer elements are short cis-regulatory regions of DNA
sequence which bind trans-acting transcription factors to enhance
gene transcription (reviewed in Maston et al. 2006)32. Cis-regula-
tory elements may lay hundreds or thousands of kilobases away
from target genes and regulate transcription over a long physical
distance. It has been suggested that small indels or point mutations
in cis-regulatory elements may be the cause of the disease, for
example in cardiovascular disease33. In addition, SNPs associated
with complex diseases such as celiac disease and type 1 diabetesFig. 3. (A) A shot from UCSC genome browser to illustrate the location of non-coding insertio
of rs11446594 is highlighted by vertical line. It is located on strong enhancer element predict
a LOGO graphic representation of ELF3 and HMGA1 transcription factor DNA-binding motifs.
as shown in the positional weight matrixes (PWMs) of ELF3 and HMGA1 DNA-binding motif
to rs11446594 A and null alleles is predicted by EEL algorithm26. Note that the variant A alle
factors, respectively.have been demonstrated to affect genes in trans34. Compared to
protein-codingmutations changes in the non-coding cis- and trans-
regulatory regions have minor effects and they are thus able to
cluster in populations, and therefore predispose to common com-
plex diseases35.
According to EEL algorithm variant rs11446594 showed
increased DNA-binding afﬁnity to ELF3 and HMGA1 transcription
factors. The exact target gene(s) regulated by this binding is not yet
known, but both factors have an important catabolic role in carti-
lage homeostasis. ELF3, also known as ESE1, belongs to ETS-domain
family of transcription factors, which are phosphorylated trans-
acting proteins regulating epithelial cell differentiation, gut devel-
opment and apoptosis36. In OA cartilage, enhanced stimulation of
ELF3 has been shown to lead to increased expression of MMP13
(matrix metalloproteinase 13)36, the major enzyme responsible for
degradation of cartilage matrix collagen37. HMGA1 (high-mobility
group A1) is a small nuclear protein that regulates for example
transcription, embryogenesis, cell cycle and DNA repair38. HMGA1
expression is increased in OA and is required for full activation of
IGFBP-3 (Insulin-like growth factor-binding protein 3). Activated
IGFBP-3 further blocks IGF-1 (insulin growth factor 1) binding to
the IGF receptor and thus decreasing the amount of effective IGF-1n rs11446594 in relation to predicted regulatory regions in HSMM cell line. The location
ed by chromHMM. (B) Genomic sequence surrounding the SNP rs11446594 is aligned to
Note that rs11446594 physically maps to an ELF3 and HMGA1 binding site, respectively,
generated by protein binding microarray27. (C) The afﬁnity of ELF3 and HMGA1 binding
le at rs11446594 may create a recognition sequence for Elf3 and HMGA1 transcription
M. Taipale et al. / Osteoarthritis and Cartilage 24 (2016) 655e663 661enabling to induce the expression of collagens and proteoglycans39.
ELF3 and HMGA1 transcription factors are important regulators of
articular cartilage homeostasis, and may regulate several OA
related genes in addition to MMP13 and IGFBP-3. Further studies
are needed to unravel the mechanism how binding of rs11446594
affects the activity of these transcription factors and further their
target genes.
At the time of discovery the MAF of rs11446597 was unknown
according to 1000 Genomes Project April 2012 release on European
subjects. However, according to updated database of 1000 Ge-
nomes Project October 2014 release on European subjects, the MAF
of rs11446597 is 0.38 and, this insertion appears to be a relatively
common variant. It has been suggested that there are multiple
common and small affecting variants which together predispose to
OA40 and common SNPs with functional evidence have previously
been associated with OA10.
The second variant rs200661871 locates between a pseudogene
WTH3D and the long intergenic non-protein coding RNA 1120 gene
(LINC01120), and resides in putative transcription factor binding
site. According to the SNP-nexus program rs200661871 was pre-
dicted to locate near OCT-1 transcription factor binding site. OCT-1
is involved in the synovial cell activity of RA patients41. These two
variants or nearby genes have not been previously associated with
OA nor have known cartilage related functions. In general, only
little is known about these genes. Previously variants in the NCKAP
gene have been associated with other complex diseases such as
bipolar disorder42.There is no previous information about MIR3679
but variants in miRNA binding regions have been associated with
complex common diseases. A link between genetic risk factors and
miRNA function has previously been shown in lumbar disc
degeneration, where the level of target gene expression was
reduced in susceptibility allele carriers43. Based on in silico bio-
informatic analyses variants rs11446594 and rs200661871 may
affect the regulation of genes responsible for OA. However, it is
possible that these genes are not neighboring ones but other genes
residing in a greater distance.
The low number of sequenced family members might have been
a limitation to the study, but earlier studies on Mendelian diseases
have shown that it is possible to identify a causative variant using
linkage analysis followed by NGS of only few affected family
members44,45. In complex diseases such as OA ﬁnding the disease
causing variant is likely to be more complicated. However, NGS has
been successfully used in identiﬁcation of causative variants in
complex diseases including prostate cancer12 and schizophrenia13.
One could also criticize the fact, that hip and knee OA cases are
pooled in this analysis. It has been suggested that there are joint
speciﬁcity in the OA process since several genes have shown
opposed changes in gene expressions in different joints46. However,
certain sequence variants have been associated not only with OA of
different joints but in different degenerative diseases. For example
a variant in the growth differentiation factor 5 gene (GDF5) has
been associated with both OA and disc degeneration47,48. Sepa-
rating the two outcomes would have diminished the statistical
linkage power in this analysis. Moreover, we were not able to
predict regulatory regions using data from chondrocytic cell lines
thus data from HSMM and GM12878 cell lines were used instead.
This may affect the predictions given the fact that transcription
factor binding patterns are heterogeneous and differ between tis-
sue types49. In addition, to best of our knowledge the identiﬁed
variants have not been previously reported to associate with OA or
any other disease in GWA studies50. Finally, the P-values obtained in
the association analyses were modest, and hence they would not
have survived correction for multiple comparisons.
In summary, we have identiﬁed two novel susceptibility vari-
ants (rs11446594 and rs200661871) for OA on chromosome 2q21,in Finnish families. The insertion rs11446594 with strong linkage is
predicted to reside within strong enhancer element between genes
NCKAP5 and MIR3679, and creates a putative recognition sequence
for ELF3 and HMGA1 transcription factors. These transcription
factors are predicted to play a signiﬁcant role in articular cartilage
homeostasis. The second insertion rs200661871 with modest
linkage locates between the WTH3D and LINC01120 genes on an
OCT-1 transcription factor binding site. Our ﬁnding strengthens the
assumption that chromosome 2 comprises multiple OA associated
variants. Further studies based on our ﬁndings may lead to iden-
tiﬁcation of new biological networks and pathways behind the OA.
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